Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Deucravacitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 known ✓ | P29597 | 20/20 | 0.94 |
| ▸ | JAK2 | O60674 | 2/20 | 0.94 |
| ▸ | JAK1 | P23458 | 2/20 | 0.94 |
| ▸ | STAT3 | P40763 | 1/20 | 0.94 |
| ▸ | STAT1 | P42224 | 1/20 | 0.94 |
| ▸ | JAK3 | P52333 | 1/20 | 0.94 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deucravacitinib SCHEMBL29424395 | 0.97 | TYK2 (1.00) | TYK2JAK2JAK1STAT3STAT1 | |
| Deucravacitinib SCHEMBL20520348 | 0.97 | TYK2 (1.00) | TYK2JAK2JAK1STAT3STAT1 | |
| Deucravacitinib SCHEMBL30278579 | 0.96 | TYK2 (0.98) | TYK2JAK2JAK1STAT3STAT1 | |
| Deucravacitinib SCHEMBL29375597 | 0.96 | TYK2 (0.98) | TYK2JAK2JAK1STAT3STAT1 | |
| Deucravacitinib SCHEMBL29619500 | 0.96 | TYK2 (0.98) | TYK2JAK2JAK1STAT3STAT1 | |
| Deucravacitinib SCHEMBL29672335 | 0.96 | TYK2 (0.90) | TYK2JAK2JAK1STAT3STAT1 | |
| Deucravacitinib SCHEMBL29672326 | 0.93 | TYK2 (0.92) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL29358231 | 0.91 | TYK2 (0.84) | TYK2JAK2JAK1STAT3STAT1 | |
| Cravacitinib SCHEMBL21091048 | 0.91 | TYK2 (1.00) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL29798957 | 0.91 | TYK2 (0.78) | TYK2JAK2JAK1STAT3STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114650990-B | Heterocyclic compounds for inhibiting TYK2 activity | 北京诺诚健华医药科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-4038063-A1 | HETEROCYCLIC COMPOUNDS FOR INHIBITING TYK2 ACTIVITIES | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2022-08-10 | — | — | EP | disclosed |
| CN-114650990-A | Heterocyclic compounds inhibiting TYK2 activity | 北京诺诚健华医药科技有限公司 | 2022-06-21 | — | — | CN | disclosed |